Recent studies have reported that, the depletion of CHD4 sensitizes cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors and DNMT inhibitors, in both hematopoietic and solid tumors [24,28,32]. Here, CHD4 is linked to cancer.